hVIVO

Vir Biotechnology Inc is an immunology company focused on combining cutting-edge technologies to treat and prevent serious infectious diseases and other serious conditions, including viral-associated diseases. Through internal development, collaborations, and acquisitions, it has four technology platforms, focused on antibodies, T cells, innate immunity, and small interfering ribonucleic acid, or siRNA. The company's pipeline consists of product candidates targeting hepatitis B, HBV, influenza A, human immunodeficiency virus, HIV, and tuberculosis, or TB. Its revenue sources are collaboration revenue, contract revenue, grant revenue, and license revenue.

Developer of polymeric therapeutics and vaccines designed to meet medical needs. The company focuses on amplifying the impact of vaccines and therapeutics by using its self-amplifying ribonucleic acid platform to provide enhanced protein expression, combining tolerability with slow release and thermostability, enabling patients to get treatment for rare diseases.

Developer of immuno-personalized diagnosis devices designed to detect bacterial and viral infections. The company's devices distinguish between bacterial and viral infections based on patients' immune responses to different infection types, enabling physicians to get rapid and actionable clinical information that guides them to make informed antibiotic treatment decisions.